HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICI) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA loci may differentially impact response to ICI. The aim of this epidemiological study was to determine the effect of HLA-A*03 as a biomarker for predicting response to immunotherapy. Methods: We studied clinical outcomes (overall survival, progression free survival or objective response) of treatment for advanced cancer in eight cohorts, including 3,339 patients treated with various ICI agents and 10,867 treated with alternative therapies. We initially modelled the association of HLA amino acid variation, followed by detailed analysis of HLA-A*03 on clinical outcomes, with replication in additional cohorts. Findings: HLA-A*03 associated in an additive manner with reduced survival after immune checkpoint inhibition (ICI) treatment in a discovery cohort (hazard ratio, 1·54 per HLA-A*03 allele; 95% confidence interval [CI] 1·20-1·96, p<0·001), validation cohort (hazard ratio, 1·22 per HLA-A*03 allele; 95% CI 1·05-1·42, p=0·009) and clinical trial for bladder cancer (hazard ratio, 1·36 per HLA-A*03 allele; CI 1·005-1·851, p=0·05). The HLA-A*03 effect was observed across ICI agents and tumor types, but not in patients treated with alternative therapies. HLA-A*03+ patients had shorter progression-free survival in three clinical trials of nivolumab for renal cell cancer (RCC, hazard ratio, 1·31; 95% CI 1·0-1·71, p=0·04), but not in the control arm. Objective responses were observed in 0% (0/8) of HLA-A*03 homozygotes in the ICI arm. HLA-A*03 associated with shorter progression-free survival in patients receiving ICI in another randomized clinical trial for RCC (avelumab/axitinib; hazard ratio, 1·59 per HLA-A*03 allele; 95%CI 1·16-2·16, p=0·004), but not those receiving control therapy. Objective responses rate was 12·5% (1/8) among HLA-A*03 homozygotes in the ICI arm. HLA-A*03 associated with impaired outcome in meta-analysis of all 3,339 ICI treated patients at genome-wide significance (p=2·01x10−8, I2=0%, 95% CI 0%-0·76%). Interpretation: HLA-A*03 carriage should be considered in decisions regarding cancer therapy involving ICI. Funding: NIH, Merck KGaA, Darmstadt, Germany and Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249
Self-citationResistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
Self-citationBraun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0839-y · Cited by 992
Self-citationPatel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590
Self-citationApolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Self-citationMotzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., Mu, X. J., Ching, K. A., Uemura, M., Pal, S. K., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1044-8 · Cited by 518
Self-citationGenomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434
Cited by
T cells specific for α-myosin drive immunotherapy-related myocarditis
Axelrod, M. L., Meijers, W. C., Screever, E. M., Qin, J., Carroll, M. G., Sun, X., Tannous, E., Zhang, Y., Sugiura, A., Taylor, B. C., et al. (2022) · Nature · doi:10.1038/s41586-022-05432-3 · Cited by 367
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Borelli, B., Antoniotti, C., Carullo, M., Germani, M. M., Conca, V., & Masi, G. (2022) · Cancers · doi:10.3390/cancers14204974 · Cited by 62
“HLA-A*03 was found to be associated with worst outcome and absence of response only in the group patients treated with ICI [47].”
BackgroundMapping the dynamic genetic regulatory architecture of HLA genes at single-cell resolution
Kang, J. B., Shen, A. Z., Gurajala, S., Nathan, A., Rumker, L., Aguiar, V. R. C., Valencia, C., Lagattuta, K. A., Zhang, F., Jonsson, A. H., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01586-6 · Cited by 49
Metadata
- Authors
- Naranbhai, V., Viard, M., Dean, M., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P., Chin, K., Wind-Rotolo, M., Mu, X. J., Robbins, P. B., Gusev, A., Choueiri, T. K., Gulley, J. L., & Carrington, M.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 23
- Issue
- 1
- Pages
- 172-184
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4200548051
- Cited by
- 113
- References
- 11
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00582-9
- The paper
- Naranbhai, V., Viard, M., Dean, M., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P., Chin, K., Wind-Rotolo, M., Mu, X. J., Robbins, P. B., Gusev, A., Choueiri, T. K., Gulley, J. L., & Carrington, M. (2022). HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00582-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.